Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Recurrent Glioblastoma Multiforme (GBM)-Pipeline Review, H1 2015

Recurrent Glioblastoma Multiforme (GBM)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Recurrent Glioblastoma Multiforme (GBM)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Recurrent Glioblastoma Multiforme (GBM)-Pipeline Review, H1 2015', provides an overview of the Recurrent Glioblastoma Multiforme (GBM)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Recurrent Glioblastoma Multiforme (GBM)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Recurrent Glioblastoma Multiforme (GBM) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Recurrent Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Recurrent Glioblastoma Multiforme (GBM) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Recurrent Glioblastoma Multiforme (GBM)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Recurrent Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Recurrent Glioblastoma Multiforme (GBM) Overview 8

Therapeutics Development 9

Pipeline Products for Recurrent Glioblastoma Multiforme (GBM)-Overview 9

Pipeline Products for Recurrent Glioblastoma Multiforme (GBM)-Comparative Analysis 10

Recurrent Glioblastoma Multiforme (GBM)-Therapeutics under Development by Companies 11

Recurrent Glioblastoma Multiforme (GBM)-Therapeutics under Investigation by Universities/Institutes 15

Recurrent Glioblastoma Multiforme (GBM)-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Recurrent Glioblastoma Multiforme (GBM)-Products under Development by Companies 19

Recurrent Glioblastoma Multiforme (GBM)-Products under Investigation by Universities/Institutes 22

Recurrent Glioblastoma Multiforme (GBM)-Companies Involved in Therapeutics Development 23

Agenus, Inc. 23

Amgen Inc. 24

AngioChem Inc. 25

Apogenix GmbH 26

AstraZeneca PLC 27

Axelar AB 28

Boehringer Ingelheim GmbH 29

Boston Biomedical, Inc. 30

Celldex Therapeutics, Inc. 31

e-Therapeutics plc 32

Eisai Co., Ltd. 33

Eli Lilly and Company 34

EnGeneIC Ltd 35

ERC Belgium SA 36

GenSpera, Inc. 37

GlaxoSmithKline plc 38

GW Pharmaceuticals plc 39

ImmunoCellular Therapeutics, Ltd. 40

Karyopharm Therapeutics, Inc. 41

Merck & Co., Inc. 42

Novartis AG 43

OncoEthix SA 44

Ono Pharmaceutical Co., Ltd. 45

Pfizer Inc. 46

Sangamo BioSciences, Inc. 47

Spectrum Pharmaceuticals, Inc. 48

Threshold Pharmaceuticals, Inc. 49

Tocagen Inc. 50

Vascular Biogenics Ltd. 51

Virttu Biologics Limited 52

ZIOPHARM Oncology, Inc. 53

Recurrent Glioblastoma Multiforme (GBM)-Therapeutics Assessment 54

Assessment by Monotherapy Products 54

Assessment by Combination Products 55

Assessment by Target 56

Assessment by Mechanism of Action 60

Assessment by Route of Administration 63

Assessment by Molecule Type 65

Drug Profiles 67

(GWP-42002 + GWP-42003)-Drug Profile 67

Ad-RTS-IL-12-Drug Profile 68

afatinib-Drug Profile 70

AMG-595-Drug Profile 74

ANG-1005-Drug Profile 76

APG-101-Drug Profile 78

axitinib-Drug Profile 80

AXL-1717-Drug Profile 83

AZD-7451-Drug Profile 85

BBI-608-Drug Profile 86

BGJ-398-Drug Profile 89

bosutinib-Drug Profile 90

buparlisib hydrochloride-Drug Profile 92

capmatinib-Drug Profile 96

dacomitinib-Drug Profile 98

Dendritic Cell Therapy for Recurrent Glioblastoma Multiforme-Drug Profile 100

DNX-2401-Drug Profile 101

doxorubicin-Drug Profile 103

ERC-1671-Drug Profile 104

erismodegib-Drug Profile 106

ETS-2101-Drug Profile 109

evofosfamide-Drug Profile 111

G-200-Drug Profile 118

galunisertib-Drug Profile 120

golvatinib + lenvatinib-Drug Profile 122

HSV-1716-Drug Profile 124

ICT-121-Drug Profile 127

lonafarnib-Drug Profile 128

MDNA-55-Drug Profile 130

mipsagargin-Drug Profile 131

nabiximols-Drug Profile 133

nivolumab-Drug Profile 136

Oncolytic Virus for Oncology-Drug Profile 142

Oncolytic Virus to Target IL-12 for Oncology-Drug Profile 143

ortataxel-Drug Profile 144

OS-2966-Drug Profile 145

OTX-015-Drug Profile 146

pazopanib hydrochloride-Drug Profile 148

pembrolizumab-Drug Profile 153

ribociclib-Drug Profile 158

rilotumumab-Drug Profile 161

rindopepimut-Drug Profile 163

SB-313-Drug Profile 165

selinexor-Drug Profile 166

SGT-53-Drug Profile 170

TPI-287-Drug Profile 172

trebananib-Drug Profile 174

Vaccine to Target Carcinoembryonic Antigen for Oncology-Drug Profile 177

vandetanib-Drug Profile 178

VB-111-Drug Profile 184

vocimagene amiretrorepvec + flucytosine ER-Drug Profile 185

Recurrent Glioblastoma Multiforme (GBM)-Recent Pipeline Updates 187

Recurrent Glioblastoma Multiforme (GBM)-Dormant Projects 274

Recurrent Glioblastoma Multiforme (GBM)-Discontinued Products 275

Recurrent Glioblastoma Multiforme (GBM)-Product Development Milestones 276

Featured News & Press Releases 276

Appendix 283

Methodology 283

Coverage 283

Secondary Research 283

Primary Research 283

Expert Panel Validation 283

Contact Us 283

Disclaimer 284

List of Tables

Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H1 2015 13

Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM)-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 16

Number of Products under Development by Companies, H1 2015 (Contd..1) 17

Number of Products under Development by Companies, H1 2015 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Investigation by Universities/Institutes, H1 2015 26

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Agenus, Inc., H1 2015 27

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Amgen Inc., H1 2015 28

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by AngioChem Inc., H1 2015 29

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Apogenix GmbH, H1 2015 30

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by AstraZeneca PLC, H1 2015 31

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Axelar AB, H1 2015 32

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Boehringer Ingelheim GmbH, H1 2015 33

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Boston Biomedical, Inc., H1 2015 34

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Celldex Therapeutics, Inc., H1 2015 35

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by e-Therapeutics plc, H1 2015 36

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Eisai Co., Ltd., H1 2015 37

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Eli Lilly and Company, H1 2015 38

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by EnGeneIC Ltd, H1 2015 39

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by ERC Belgium SA, H1 2015 40

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by GenSpera, Inc., H1 2015 41

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by GlaxoSmithKline plc, H1 2015 42

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by GW Pharmaceuticals plc, H1 2015 43

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2015 44

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 45

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Merck & Co., Inc., H1 2015 46

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Novartis AG, H1 2015 47

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by OncoEthix SA, H1 2015 48

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 49

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Pfizer Inc., H1 2015 50

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Sangamo BioSciences, Inc., H1 2015 51

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 52

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 53

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Tocagen Inc., H1 2015 54

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Vascular Biogenics Ltd., H1 2015 55

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by Virttu Biologics Limited, H1 2015 56

Recurrent Glioblastoma Multiforme (GBM)-Pipeline by ZIOPHARM Oncology, Inc., H1 2015 57

Assessment by Monotherapy Products, H1 2015 58

Assessment by Combination Products, H1 2015 59

Number of Products by Stage and Target, H1 2015 61

Number of Products by Stage and Mechanism of Action, H1 2015 65

Number of Products by Stage and Route of Administration, H1 2015 68

Number of Products by Stage and Molecule Type, H1 2015 70

Recurrent Glioblastoma Multiforme (GBM) Therapeutics-Recent Pipeline Updates, H1 2015 191

Recurrent Glioblastoma Multiforme (GBM)-Dormant Projects, H1 2015 278

Recurrent Glioblastoma Multiforme (GBM)-Discontinued Products, H1 2015 279

List of Figures

Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H1 2015 13

Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM)-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 15

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 21

Assessment by Monotherapy Products, H1 2015 58

Number of Products by Top 10 Targets, H1 2015 60

Number of Products by Stage and Top 10 Targets, H1 2015 61

Number of Products by Top 10 Mechanism of Actions, H1 2015 64

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 64

Number of Products by Top 10 Routes of Administration, H1 2015 67

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 67

Number of Products by Top 10 Molecule Types, H1 2015 69

Number of Products by Stage and Top 10 Molecule Types, H1 2015 69

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Agenus, Inc.

Amgen Inc.

AngioChem Inc.

Apogenix GmbH

AstraZeneca PLC

Axelar AB

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Celldex Therapeutics, Inc.

e-Therapeutics plc

Eisai Co., Ltd.

Eli Lilly and Company

EnGeneIC Ltd

ERC Belgium SA

GenSpera, Inc.

GlaxoSmithKline plc

GW Pharmaceuticals plc

ImmunoCellular Therapeutics, Ltd.

Karyopharm Therapeutics, Inc.

Merck & Co., Inc.

Novartis AG

OncoEthix SA

Ono Pharmaceutical Co., Ltd.

Pfizer Inc.

Sangamo BioSciences, Inc.

Spectrum Pharmaceuticals, Inc.

Threshold Pharmaceuticals, Inc.

Tocagen Inc.

Vascular Biogenics Ltd.

Virttu Biologics Limited

ZIOPHARM Oncology, Inc.

Recurrent Glioblastoma Multiforme (GBM) Therapeutic Products under Development, Key Players in Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Recurrent Glioblastoma Multiforme (GBM) Pipeline Overview, Recurrent Glioblastoma Multiforme (GBM) Pipeline, Recurrent Glioblastoma Multiforme (GBM) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com